证券日报网讯 12月10日晚间，中恒集团发布公告称，为满足公司控股子公司中恒中药材日常经营和业 务发展需求，确保中恒中药材生产经营活动的顺利开展，公司为中恒中药材向金融机构申请融资提供连 带责任保证，具体情况如下：2025年12月9日，公司与上海浦东发展银行股份有限公司南宁分行（简 称"浦发银行南宁分行"）签订了《最高额保证合同》，为中恒中药材与浦发银行南宁分行签署的《流动 资金贷款合同》项下债务提供最高金额不超过人民币2，999.9556万元的连带责任保证担保，保证期间 自每笔债权合同债务履行期届满之日起至该债权合同约定的债务履行期届满之日后三年止。本次担保无 反担保。 （文章来源：证券日报） ...

Group 1 - The core point of the article is that Zhongheng Group announced that its subsidiary, Chongqing Laimei Pharmaceutical Co., Ltd., received two medical device registration certificates from the Hainan Provincial Drug Administration [2] Group 2 - The medical device registration certificates were issued to Hainan Laimei Medical Devices Co., Ltd., a subsidiary of Chongqing Laimei Pharmaceutical [2] - This development indicates a positive regulatory milestone for the company in the medical device sector [2] - The announcement was made on the evening of December 10 [2]

Core Viewpoint - Zhongheng Group (600252.SH) announced that its subsidiary, Chongqing Laimei Pharmaceutical Co., Ltd., received two medical device registration certificates from the Hainan Provincial Drug Administration for its products, enhancing its competitive edge in the medical device market [1] Group 1: Product Registration - The registered products include a medical electronic endoscope image processor (registration number: Qiong Xie Zhu Zheng 20252060115) and an electronic bronchoscope (registration number: Qiong Xie Zhu Zheng 20252060116) [1] - These products are developed by Laimei Medical Devices and are designed to directly observe patient images, aiding in clinical diagnosis and treatment [1] Group 2: Market Impact - The certification of these products will diversify the company's medical device offerings, meeting the varied demands of the market [1] - This development is expected to positively impact the company's future operations and enhance its overall competitiveness [1]

Group 1 - The core point of the article is that Zhongheng Group has reported a guarantee balance of approximately 369 million yuan, which accounts for 6.12% of the company's audited net assets for 2024 [1] - As of the announcement date, Zhongheng Group's market capitalization is 9.1 billion yuan [1] - The revenue composition for Zhongheng Group in 2024 is as follows: 76.26% from pharmaceutical manufacturing, 13.84% from other businesses, and 9.9% from food [1]

本次获证产品的实际销售情况取决于未来市场推广效果，目前尚无法预测其 对公司未来业绩的具体影响。敬请广大投资者谨慎决策，注意投资风险。 证券代码：600252 证券简称：中恒集团 公告编号：临 2025-95 广西梧州中恒集团股份有限公司 关于控股孙公司获得医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，广西梧州中恒集团股份有限公司（以下简称"公司"或"中恒集团"） 控股子公司重庆莱美药业股份有限公司之子公司海南莱美医疗器械有限公司（以 下简称"莱美医疗器械"）收到海南省药品监督管理局颁发的两项《医疗器械注 册证》。现将有关事项公告如下： 二、对公司的影响及风险提示 本次控股孙公司获证的医用电子内窥镜图像处理器及电子支气管镜，是莱美 医疗器械研发的内窥镜产品，该产品能直接观察患者图像，有利于临床使用对患 者病症的判断及治疗。此次控股孙公司产品获证将进一步丰富公司医疗器械产品 种类，满足市场多样化的需求，提升公司综合竞争力，对未来经营将产生积极影 响。 特此公告。 （以下无正文） 2 （此页无正文，仅为 ...

担保对象及基本情况 证券代码：600252 证券简称：中恒集团 公告编号：临 2025-96 广西梧州中恒集团股份有限公司 关于为控股子公司中恒中药材提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 对外担保逾期的累计金额（万元） | 无 | | --- | --- | | 截至本公告日上市公司及其控股子公司对外担保总额（万元） | 36,873.62 | | 对外担保总额占上市公司最近一期经审计净资产的比例（%） | 6.12 | 一、担保情况概述 （一） 担保的基本情况 为满足广西梧州中恒集团股份有限公司（以下简称"公司"或"中恒集团"） 控股子公司中恒中药材日常经营和业务发展需求，确保中恒中药材生产经营活动 的顺利开展，公司为中恒中药材向金融机构申请融资提供连带责任保证，具体情 况如下： 2025 年 12 月 9 日，公司与上海浦东发展银行股份有限公司南宁分行（以下 简称"浦发银行南宁分行"）签订了《最高额保证合同》，为中恒中药材与浦发银 行南宁分行签署的《流动资金贷款合同》项下债务提 ...

Group 1 - The core point of the article is that Zhongheng Group announced the receipt of two medical device registration certificates for its subsidiary, Hainan Laimei Medical Equipment Co., Ltd., from the Hainan Provincial Drug Administration, including a "medical electronic endoscope image processor" [1] - For the fiscal year 2024, Zhongheng Group's revenue composition is as follows: 76.26% from pharmaceutical manufacturing, 13.84% from other businesses, and 9.9% from food [1] - As of the report date, Zhongheng Group has a market capitalization of 9.1 billion yuan [1]

Core Viewpoint - Zhongheng Group announced that its subsidiary, Chongqing Laimei Pharmaceutical Co., Ltd., received two medical device registration certificates from the Hainan Provincial Drug Administration for its medical electronic endoscope image processor and electronic bronchoscope, which are beneficial for clinical diagnosis and treatment of patients [1] Group 1 - The medical devices certified include an electronic endoscope image processor and an electronic bronchoscope [1] - The products developed by Laimei Medical Equipment allow direct observation of patient images, aiding in clinical judgment and treatment of conditions [1]

Core Insights - Zhongheng Group (600252.SH) announced that its subsidiary, Chongqing Laimei Pharmaceutical, received two medical device registration certificates from the Hainan Provincial Drug Administration for a medical electronic endoscope image processor and an electronic bronchoscope, both valid from November 17, 2025, to November 16, 2030 [1] Company Developments - The newly certified products allow direct observation of patient images, aiding in clinical diagnosis and treatment [1] - The certification will enhance the variety of medical device products offered by the company, meeting diverse market demands and improving overall competitiveness [1] - The positive impact on future operations is anticipated as a result of these developments [1]

转自：新华财经 12月4日至5日，以"智聚八桂 医路同行"为主题的"2025金融赋能医疗健康产业（广西）创新会议"在广西南宁成功举办。知名医药院校专家、医疗健康产业 龙头企业、金融投资机构及东盟代表，共同探讨在科技创新与制度变革双轮驱动下，如何构建"科技创新+资本赋能+产业落地"的闭环生态，助力广西打造 面向东盟的医疗健康产业高地。 这一活动由中共广西壮族自治区党委金融委员会办公室指导，国海证券、中恒集团、国海创新资本主办，广西（上海）产业合作中心协办，融中承办。 自治区党委金融办资本市场处负责人在致辞时表示，随着政策支持体系的持续完善和"科技创新+资本赋能+产业落地"的生态构建需求凸显，广西医疗健康 产业正迎来高质量发展的关键阶段，为金融资本深度参与、共创产业新蓝海提供了广阔空间。他希望各界聚焦广西"3+3"大健康产业体系，深耕重点领域， 加速科技成果在广西转化落地，精准匹配产业需求，推动创新链、产业链、资金链深度融合，助力广西打造面向东盟重要的生物医药制造基地，共拓东盟跨 境合作空间。 国海证券党委书记、董事长王海河表示，国海证券是扎根广西、服务全国的综合性上市券商，多年来始终将支持医疗健康产业发展作为服 ...